{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=toripalimab", "query": { "intervention": "toripalimab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=toripalimab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T14:54:52.533Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05031494", "title": "A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "YH003", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eucure (Beijing) Biopharma Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-12-08", "completion_date": "2023-08-16", "has_results": false, "last_update_posted_date": "2025-01-06", "last_synced_at": "2026-09-02T14:54:52.533Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05031494" }, { "nct_id": "NCT05757492", "title": "Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non-Small Cell Lung Cancer", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "CHS-006 (anti-TIGIT)", "type": "DRUG" }, { "name": "toripalimab (anti-PD-1)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2023-04-26", "completion_date": "2024-07-31", "has_results": false, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-09-02T14:54:52.533Z", "location_count": 4, "location_summary": "Orlando, Florida • Detroit, Michigan • Reno, Nevada + 1 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Reno", "state": "Nevada" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05757492" }, { "nct_id": "NCT05479045", "title": "A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer Stage IV", "Ovarian Cancer Stage III", "Ovarian Cancer Stage 3" ], "interventions": [ { "name": "NY-ESO-1 Peptide vaccine", "type": "BIOLOGICAL" }, { "name": "Toripalimab-tpzi", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2026-09", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-09-02T14:54:52.533Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05479045" }, { "nct_id": "NCT07796126", "title": "Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2026-09-30", "completion_date": "2029-05-29", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-02T14:54:52.533Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07796126" }, { "nct_id": "NCT04645069", "title": "ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "ADG126 Mono", "type": "BIOLOGICAL" }, { "name": "ADG126-anti PD1", "type": "BIOLOGICAL" }, { "name": "ADG126-ADG106", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Adagene Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2021-03-15", "completion_date": "2024-05-17", "has_results": false, "last_update_posted_date": "2024-08-14", "last_synced_at": "2026-09-02T14:54:52.533Z", "location_count": 2, "location_summary": "Los Angeles, California • San Antonio, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04645069" }, { "nct_id": "NCT04387084", "title": "Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Skin Neoplasm", "Metastatic Malignant Skin Neoplasm" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Short-Term Fasting", "type": "OTHER" }, { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Toripalimab", "type": "BIOLOGICAL" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-08-12", "completion_date": "2027-08-12", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-09-02T14:54:52.533Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04387084" }, { "nct_id": "NCT04137900", "title": "Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Unresectable Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "TAB004", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TopAlliance Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 499, "start_date": "2019-10-30", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2024-02-05", "last_synced_at": "2026-09-02T14:54:52.533Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04137900" }, { "nct_id": "NCT07423078", "title": "Window of Opportunity in Preserving Laryngeal Function Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)", "Locally Advanced Laryngeal Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Matthew Spector", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2026-04-06", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-02T14:54:52.533Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07423078" }, { "nct_id": "NCT07209189", "title": "Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Squamous Cell Carcinoma", "Oral Cavity Cancer", "Oropharyngeal Cancer", "Laryngeal Cancer", "Sinonasal Squamous Cell Carcinoma", "HPV (Human Papillomavirus)-Associated Carcinoma", "Skull Base Tumors", "HPV 16 Positive Oropharyngeal Tumors (OPC)" ], "interventions": [ { "name": "Toripalimab + Chemotherapy", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" }, { "name": "Chemoradiotherapy or radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2026-02-18", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-02T14:54:52.533Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07209189" }, { "nct_id": "NCT07277322", "title": "Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Liver Metastases" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Feng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-09-01", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-02T14:54:52.533Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07277322" } ] }